GentiBio
Scott Hussel is Development Scientist, working in the Product Sciences and Characterization group at GentiBio. Prior to joining GentiBio’s Product Sciences team, Scott held a similar position with Juno/BMS where he helped design multiple analytical tools to provide support for the development of early and late-stage CAR-T programs. Scott has over 20yrs of experience in both oncology and inflammation drug development, working for several Seattle-based companies including ICOS, Trubion Pharmaceuticals, and Novo Nordisk.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.